Related references
Note: Only part of the references are listed.Single-fraction HDR brachytherapy as monotherapy in low and intermediate risk prostate cancer: Outcomes from two clinical trials with and without an MRI-guided boost
Yasir Alayed et al.
RADIOTHERAPY AND ONCOLOGY (2021)
Dosimetry of local failure with single dose 19 Gy high-dose-rate brachytherapy for prostate cancer
Shreya Armstrong et al.
RADIOTHERAPY AND ONCOLOGY (2021)
Ultra-hypofractionated radiotherapy for low- and intermediate risk prostate cancer: High-dose-rate brachytherapy vs stereotactic ablative radiotherapy
Yat Man Tsang et al.
RADIOTHERAPY AND ONCOLOGY (2021)
Prostate high dose-rate brachytherapy as monotherapy for prostate cancer: Late toxicity and patient reported outcomes from a randomized phase II clinical trial
Mark Corkum et al.
RADIOTHERAPY AND ONCOLOGY (2021)
Safety and Efficacy of Virtual Prostatectomy With Single-Dose Radiotherapy in Patients With Intermediate-Risk Prostate Cancer Results From the PROSINT Phase 2 Randomized Clinical Trial
Carlo Greco et al.
JAMA ONCOLOGY (2021)
Toxicity at 1 Year After Stereotactic Body Radiation Therapy in 3 Fractions for Localized Prostate Cancer
Alessandro Magli et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2021)
Single dose high-dose-rate brachytherapy with focal dose escalation for prostate cancer: Mature results of a phase 2 clinical trial
Shreya Armstrong et al.
RADIOTHERAPY AND ONCOLOGY (2021)
Single dose high-dose rate (HDR) brachytherapy (BT) as monotherapy for localised prostate cancer: Early results of a UK national cohort study
Hannah Tharmalingam et al.
RADIOTHERAPY AND ONCOLOGY (2020)
HDR Prostate Brachytherapy
Juanita Crook et al.
SEMINARS IN RADIATION ONCOLOGY (2020)
Pattern of relapse and dosimetric analysis of a single dose 19 Gy HDR-brachytherapy phase II trial
Alfonso Gomez-Iturriaga et al.
RADIOTHERAPY AND ONCOLOGY (2020)
Prostate high dose -rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy
Gerard Morton et al.
RADIOTHERAPY AND ONCOLOGY (2020)
Urinary Morbidity in Men Treated With Stereotactic Body Radiation Therapy (SBRT) for Localized Prostate Cancer Following Transurethral Resection of the Prostate (TURP)
Abigail Pepin et al.
FRONTIERS IN ONCOLOGY (2020)
Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer in Men With a High Baseline International Prostate Symptom Score (IPSS ≥ 15)
Nima Aghdam et al.
FRONTIERS IN ONCOLOGY (2020)
Is prostate brachytherapy a dying art? Trends and variation in the definitive management of prostate cancer in Ontario, Canada
Mark T. Corkum et al.
RADIOTHERAPY AND ONCOLOGY (2020)
Patient-reported health-related quality of life outcomes after HDR brachytherapy between small (<60 cc) and large (≥60 cc) prostate glands
Robert H. Press et al.
BRACHYTHERAPY (2019)
Five-Year Outcomes of a Single-Institution Prospective Trial of 19-Gy Single-Fraction High-Dose-Rate Brachytherapy for Low- and Intermediate-Risk Prostate Cancer
Zaid A. Siddiqui et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2019)
Dose Escalation for Prostate Adenocarcinoma: A Long-Term Update on the Outcomes of a Phase 3, Single Institution Randomized Clinical Trial
Dario Pasalic et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2019)
Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of Over 6,000 Patients Treated On Prospective Studies
William C. Jackson et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2019)
Two StereoTactic ablative radiotherapy treatments for localized prostate cancer (2STAR): Results from a prospective clinical trial
Yasir Alayed et al.
RADIOTHERAPY AND ONCOLOGY (2019)
Safety of Prostate Stereotactic Body Radiation Therapy after Transurethral Resection of Prostate (TURP): A Propensity Score Matched Pair Analysis
Vedang Murthy et al.
PRACTICAL RADIATION ONCOLOGY (2019)
Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial
Anders Widmark et al.
LANCET (2019)
Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial
Douglas H. Brand et al.
LANCET ONCOLOGY (2019)
A phase I dose-escalation trial of stereotactic body radiotherapy using 4 fractions for patients with localized prostate cancer
Takuro Kainuma et al.
RADIATION ONCOLOGY (2019)
MRI assisted focal boost integrated with HDR monotherapy study in low and intermediate risk prostate cancer (MARS): Results from a phase II clinical trial
Yasir Alayed et al.
RADIOTHERAPY AND ONCOLOGY (2019)
Single fraction urethra-sparing prostate cancer SBRT: Phase I results of the ONE SHOT trial
Thomas Zilli et al.
RADIOTHERAPY AND ONCOLOGY (2019)
High-dose-rate interstitial brachytherapy as monotherapy in one fraction of 20.5 Gy for the treatment of localized prostate cancer: Toxicity and 6-year biochemical results
Pedro J. Prada et al.
BRACHYTHERAPY (2018)
Pattern of relapse and dose received by the recurrent intraprostatic nodule in low- to intermediate-risk prostate cancer treated with single fraction 19 Gy high-dose-rate brachytherapy
Lucas C. Mendez et al.
BRACHYTHERAPY (2018)
The Transcriptional Landscape of Radiation-Treated Human Prostate Cancer: Analysis of a Prospective Tissue Cohort
Simon P. Keam et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2018)
Dose Response and Fractionation Sensitivity of Prostate Cancer After External Beam Radiation Therapy: A Meta-analysis of Randomized Trials
Ivan R. Vogelius et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2018)
High dose rate brachytherapy as monotherapy for localised prostate cancer
Iosif Strouthos et al.
RADIOTHERAPY AND ONCOLOGY (2018)
High dose rate brachytherapy for prostate cancer: A prospective toxicity evaluation of a one day schedule including two 13.5 Gy fractions
Gorka Nagore et al.
RADIOTHERAPY AND ONCOLOGY (2018)
Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer The NRG Oncology RTOG 0126 Randomized Clinical Trial
Jeff M. Michalski et al.
JAMA ONCOLOGY (2018)
ONE SHOT - single shot radiotherapy for localized prostate cancer: study protocol of a single arm, multicenter phase I/II trial
Thomas Zilli et al.
RADIATION ONCOLOGY (2018)
Phase 2 Multicenter Trial of Heterogeneous-dosing Stereotactic Body Radiotherapy for Low- and Intermediate-risk Prostate Cancer: 5-year Outcomes
Donald B. Fuller et al.
EUROPEAN UROLOGY ONCOLOGY (2018)
Stereotactic ablative body radiotherapy in patients with prostate cancer
Andrew Loblaw et al.
TRANSLATIONAL ANDROLOGY AND UROLOGY (2018)
Exploring Value From the Patient's Perspective Between Modern Radiation Therapy Modalities for Localized Prostate Cancer
Narek Shaverdian et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2017)
Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer
Charles N. Catton et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Early toxicity and quality-of life results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy
Gerard Morton et al.
RADIOTHERAPY AND ONCOLOGY (2017)
Single-dose high-dose-rate brachytherapy compared to two and three fractions for locally advanced prostate cancer
Peter Hoskin et al.
RADIOTHERAPY AND ONCOLOGY (2017)
High-Dose Robotic Stereotactic Body Radiotherapy in the Treatment of Patients With Prostate Cancer: Preliminary Results in 26 Patients
A. Pontoriero et al.
TECHNOLOGY IN CANCER RESEARCH & TREATMENT (2016)
The decreased use of brachytherapy boost for intermediate and high-risk prostate cancer despite evidence supporting its effectiveness
Peter F. Orio et al.
BRACHYTHERAPY (2016)
Outcomes Associated With 3 Treatment Schedules of High-Dose-Rate Brachytherapy Monotherapy for Favorable-Risk Prostate Cancer
Maha Saada Jawad et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2016)
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial
David Dearnaley et al.
LANCET ONCOLOGY (2016)
High-dose-rate interstitial brachytherapy as monotherapy in one fraction for the treatment of favorable stage prostate cancer: Toxicity and long-term biochemical results
Pedro J. Prada et al.
RADIOTHERAPY AND ONCOLOGY (2016)
High-dose-rate brachytherapy as a monotherapy for prostate cancer-Single-institution results of the extreme fractionation regimen
Andrzej Marek Kukielkal et al.
BRACHYTHERAPY (2015)
Hematuria following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer
Marie K. Gurka et al.
RADIATION ONCOLOGY (2015)
Declining use of brachytherapy for the treatment of prostate cancer
Usama Mahmood et al.
BRACHYTHERAPY (2014)
Late toxicity and five year outcomes after high-dose-rate brachytherapy as a monotherapy for localized prostate cancer
Pirus Ghadjar et al.
RADIATION ONCOLOGY (2014)
Stereotactic body radiation therapy (SBRT) for prostate cancer in men with large prostates (≥50 cm3)
Einsley Janowski et al.
RADIATION ONCOLOGY (2014)
Virtual HDR CyberKnife SBRT for localized prostatic carcinoma: 5-year disease-free survival and toxicity observations
Donald Blake Fuller et al.
FRONTIERS IN ONCOLOGY (2014)
A comparative dosimetric analysis of virtual stereotactic body radiotherapy to high-dose-rate monotherapy for intermediate-risk prostate cancer
Daniel E. Spratt et al.
BRACHYTHERAPY (2013)
High-Dose-Rate Interstitial Brachytherapy as Monotherapy for Clinically Localized Prostate Cancer: Treatment Evolution and Mature Results
Nikolaos Zamboglou et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2013)
High dose rate brachytherapy as monotherapy for localised prostate cancer: a hypofractionated two-implant approach in 351 consecutive patients
Nikolaos Tselis et al.
RADIATION ONCOLOGY (2013)
Stereotactic body radiotherapy with a focal boost to the MRI-visible tumor as monotherapy for low- and intermediate-risk prostate cancer: early results
Shafak Aluwini et al.
RADIATION ONCOLOGY (2013)
High-dose-rate interstitial brachytherapy as monotherapy in one fraction and transperineal hyaluronic acid injection into the perirectal fat for the treatment of favorable stage prostate cancer: Treatment description and preliminary results
Pedro J. Prada et al.
BRACHYTHERAPY (2012)
American Brachytherapy Society consensus guidelines for high-dose-rate prostate brachytherapy
Yoshiya Yamada et al.
BRACHYTHERAPY (2012)
STEREOTACTIC BODY RADIOTHERAPY AS MONOTHERAPY OR POST-EXTERNAL BEAM RADIOTHERAPY BOOST FOR PROSTATE CANCER: TECHNIQUE, EARLY TOXICITY, AND PSA RESPONSE
Siavash Jabbari et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2012)
HIGH-DOSE-RATE BRACHYTHERAPY AS A MONOTHERAPY FOR FAVORABLE-RISK PROSTATE CANCER: A PHASE II TRIAL
Maroie Barkati et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2012)
URETHRA-SPARING, INTRAOPERATIVE, REAL-TIME PLANNED, PERMANENT-SEED PROSTATE BRACHYTHERAPY: TOXICITY ANALYSIS
Thomas Zilli et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2011)
HIGH-DOSE-RATE MONOTHERAPY: SAFE AND EFFECTIVE BRACHYTHERAPY FOR PATIENTS WITH LOCALIZED PROSTATE CANCER
D. Jeffrey Demanes et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2011)
MONOTHERAPEUTIC HIGH-DOSE-RATE BRACHYTHERAPY FOR PROSTATE CANCER: FIVE-YEAR RESULTS OF AN EXTREME HYPOFRACTIONATION REGIMEN WITH 54 GY IN NINE FRACTIONS
Yasuo Yoshioka et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2011)
Image-guided stereotactic body radiation therapy for localized prostate cancer
Jin-Kyu Kang et al.
TUMORI JOURNAL (2011)
High-Dose-Rate Prostate Brachytherapy An Excellent Accelerated-Hypofractionated Treatment for Favorable Prostate Cancer
Alvaro A. Martinez et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2010)
Previous transurethral resection of the prostate is not a contraindication to high-dose rate brachytherapy for prostate cancer
Hao Lun Luo et al.
BJU INTERNATIONAL (2009)
GENITOURINARY TOXICITY AFTER HIGH-DOSE-RATE (HDR) BRACHYTHERAPY COMBINED WITH HYPOFRACTIONATED EXTERNAL BEAM RADIOTHERAPY FOR LOCALIZED PROSTATE CANCER: AN ANALYSIS TO DETERMINE THE CORRELATION BETWEEN DOSE-VOLUME HISTOGRAM PARAMETERS IN HDR BRACHYTHERAPY AND SEVERITY OF TOXICITY
Hiromichi Ishiyama et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2009)
Virtual HDRSM cyberknife treatment for localized prostatic carcinoma:: Dosimetry comparison with hdr brachytherapy and preliminary clinical observations
Donald B. Fuller et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2008)
Patient and treatment factors associated with complications after prostate brachytherapy
Aileen B. Chen et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
The influence of isotope and prostate volume on urinary morbidity after prostate brachytherapy
A Niehaus et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2006)
The impact of prostate volume following neoadjuvant androgen deprivation on quality of life and voiding symptoms in patients undergoing permanent prostate brachytherapy
T Krupski et al.
EUROPEAN UROLOGY (2003)
Risk factors for acute urinary retention requiring temporary intermittent catheterization after prostate brachytherapy: A prospective study
J Locke et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2002)
Share Paper
